...How did a failed contraceptive become the first targeted therapy for t...Today at the 2008 Annual Meeting of the American Association for the A...As both a preventative and therapeutic agent tamoxifen has been credi...In the 1970s Jordans laboratory pioneered the work that turned tamoxi...

How did a failed contraceptive become the first targeted therapy for the treatment of breast cancer" The transformation of tamoxifen, from cast-off to lifesaver, laid the foundation for a new class of therapeutics selective estrogen receptor modulators that could treat or prevent a variety of human diseases, including cancer and osteoporosis, according to V. Craig Jordan, OBE, Ph.D., D.Sc., a researcher at the Fox Chase Cancer Center in Philadelphia.

Today at the 2008 Annual Meeting of the American Association for the Advancement of Science, Jordan reports on efforts to use the lessons learned about tamoxifen to develop new hormone receptor-related drugs for both women and men. His presentation will be part of a symposium, held from 1:45 p.m. to 4:45 p.m., entitled Progress in Cancer Prevention.

As both a preventative and therapeutic agent, tamoxifen has been credited with saving the lives of more than a half million women over the last 30 years, says Jordan, the Alfred G. Knudson Jr., M.D., Ph.D., Chair in Cancer Research at Fox Chase. The process of discovery that made tamoxifen a reality has given us insights into molecular mechanisms that are currently being used to advance the creation and refinement of better drugs.

In the 1970s, Jordans laboratory pioneered the work that turned tamoxifen into a cancer therapy, which then jump-started a field of study into so-called designer estrogens. These drugs, called selective estrogen receptor modulators (SERMS), can have different effects on their targets, estrogen receptors, depending on where the receptor is located within a woman's body. The SERM raloxifene, for example, exhibits an anti-estrogen activity that can prevent cancer in breast tissue, but in other tissue the same drug has an estrogen-like effect that increases bone density. Currently, raloxifene, which was also developed in Jordans laboratory, is approved in post-menopausal women to prevent osteoporosis and treat brea'/>"/>

(Date:7/31/2015)... , ... July 31, 2015 , ... ... important workshop at its new True North Conference Center. The medical community, social ... the Jacksonville community may be more aligned in the effort to better understand ...

(Date:7/31/2015)... ... July 31, 2015 , ... Coco Libre announced today ... media, and VIPs at the 2015 Vans US Open of Surfing, July 25 through ... can claim “no added sugar” on the market, is a natural choice given the ...

(Date:7/31/2015)... ... , ... Ticket Down is a reliable source of authentic Hamilton tickets ... refreshing show on Broadway, look no further than Hamilton. This American musical is critically ... Circle Award, Drama Desk Award, Lucille Lortel Award, and New York Drama Critics’ Award. ...

(Date:7/31/2015)... ... July 31, 2015 , ... According to an article published ... if they could reach a consensus on the steps that need to be taken ... group reached 90 percent consensus on a series of steps that each surgeon must ...

(Date:7/31/2015)... York, New York (PRWEB) , ... ... ... renowned trial attorney Jason T. Brown’s live lecture on pharmaceutical negligence is ... July 28th, 2015 was well received with a 94% approval rating from ...

... including Parkinson's, Alzheimer's, Diffuse Lewy body disease, and ... Most commonly they become symptomatic due to a ... case of Parkinson's it is dopamine. When the ... impaired, which occurs with oxidation, the eventual results ...

... to diagnose and many a times the diagnosis is ... emerging as a promising technique for early diagnosis of ... facilitating rapid amplification of small amounts of a genome ... Urology Congress in India. Presence of even one ...

... (PPA),is a common ingredient found in many non-prescription cough ... remedies increased the risk of stroke by 23 percent. ... says, "Case reports have linked exposure to PPA to ... ,A hemorrhagic stroke results when an artery wall ruptures ...

... of India has successfully undergone left knee joint replacement by ... "The operation, which started at around 10 a.m., was completed ... satisfaction," Dr. Ranawat said at a press briefing. ``He (Mr. ... now in the recovery room. He is not on any ...

... injectable contraceptive pill has been approved by the Food ... than 99 percent effective when women get the shot ... the pill., ,Lunelle is an alternative to another ... works Like many other birth control pills as it ...

... that more than two-thirds of births in Russia are marred ... clinic is suffering health problems. , ,The number of ... 30 percent last year, said Olga Frolova, head of the ... that the decline is due to the spread of heavy ...

(Date:7/30/2015)... 30, 2015 Edwards Lifesciences Corporation (NYSE: EW ... and hemodynamic monitoring, today announced that Robert A. Ingram ... "Bob is an ardent champion for innovation in the ... have him on Edwards, board as we pursue our focused ... and CEO. "Bob has provided a valuable perspective to our ...

(Date:7/30/2015)... VIEW, Calif. , July 30, 2015 ... it will release its second quarter 2015 financial results ... 2015. In conjunction with the release, the Company ... at 5:00 p.m. Eastern Time on ... of the quarter and other business developments. ...

... , , CAMBRIDGE, Mass. , ... it has reached an agreement with the U.S. Food and Drug ... trial for Vascugel®, an investigational new drug for the prevention of ... Special Protocol Assessment (SPA) procedure. Pervasis expects to initiate the study ...